Last reviewed · How we verify
Upstene (INDALPINE)
Upstene, also known as INDALPINE, is a small molecule modality developed by an unknown entity. Its current owner is also unknown. The target and drug class of Upstene are not specified. There is no information available on its FDA approval status, approved indications, half-life, bioavailability, generic manufacturers, or off-patent status. As a result, there is limited information available on its commercial status and key safety considerations.
At a glance
| Generic name | INDALPINE |
|---|---|
| Target | Sodium-dependent serotonin transporter |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Upstene CI brief — competitive landscape report
- Upstene updates RSS · CI watch RSS